Skip to main content
. 2015 Feb 19;6(6):4516–4526. doi: 10.18632/oncotarget.2799

Table 3. Clinicopathological features by GOT1 status in the validation cohort.

Characteristic Validation Cohort N = 140 GOT1+ N = 73 GOT1– N = 67 P high vs. low
Sex, n (%)
 male 70 (50%) 32 (44%) 38 (57%) 0.18
 female 70 (50%) 41 (56%) 29 (43%)
Age
 Median 71 71 70 0.70
 Range 21–89 21–89 33–85
 Age ≥ 65 n (%) 96 (69%) 50 (68%) 46 (69%) 1.0
Site, n (%)
 Head 80 (58%) 42 (58%) 38 (57%) 0.89
 Body 37 (26%) 20 (27%) 17 (25%)
 Tail 23 (16%) 11 (15%) 12 (18%)
Tumor Size, n (%)
 T1/2 10 (12%) 7 (14%) 3 (10%) 0.73
 T3/4 70 (88%) 42 (86%) 28 (90%)
Nodal Metastasis, n (%)
 N0 22 (28%) 15 (31%) 7 (23%) 0.45
 N1 57 (72%) 33 (69%) 24 (77%)
Systemic Metastasis, n (%)
 M0 51 (39%) 33 (49%) 18 (29%) 0.03
 M1 79 (61%) 35 (51%) 44 (71%)
Stage Grouping*, n (%)
 I/II 46* (36%) 29 (44%) 17 (27%) 0.07
 III/IV 82* (64%) 37 (56%) 45 (73%)
Stage Grouping*, n (%)
 I/II/III 47 (37%) 29 (44%) 18 (29%) 0.09
 IV 81 (63%) 37 (56%) 44 (71%)
Histological Grade, n (%)
 G1/2 84 (60%) 49 (67%) 35 (52%) 0.09
 G3/4 56 (40%) 24 (33%) 32 (48%)

Abbreviations: GOT1, Aspartate Aminotransferase 1; Stage grouping according to AJCC. Note: we tallied both stage groupings to illustrate that there was only one stage III patient (GOT1–) in the combined advanced or systemic group (i.e., stage III/IV) group.